Risk of pediatric celiac disease according to HLA haplotype and country by Liu, Edwin et al.
 
 
This document has been downloaded from  
TamPub – The Institutional Repository of University of Tampere 
 
 
Publisher's version http://urn.fi/URN:NBN:fi:uta-201602171226  
 
  
Author(s):  
Liu, Edwin; Lee, Hye-Seung; Aronsson, Carin A; Virtanen, Suvi; 
Hyöty, Heikki; Korkeasalo, Mirva; Kurppa, Kalle; Lönnrot, Maria; 
Riikonen, Anne; Åkerlund, Mari et al.  
Title:  Risk of pediatric celiac disease according to HLA haplotype and country 
Year:  2014 
Journal 
Title:  New England Journal of Medicine 
Vol and 
number:  371 : 1  
Pages:  42-49 
ISSN:  0028-4793 
Discipline:  Biomedicine; Gynaecology and paediatrics; Health care science 
School 
/Other Unit: School of Medicine; School of Health Sciences 
Item Type:  Journal Article 
Language:  en 
DOI:  http://dx.doi.org/10.1056/NEJMoa1313977  
URN:  URN:NBN:fi:uta-201602171226 
URL:  http://www.nejm.org/doi/pdf/10.1056/NEJMoa1313977 
 
 
 
 
 
 
 
 
All material supplied via TamPub is protected by copyright and other intellectual 
property rights, and duplication or sale of all part of any of the repository collections 
is not permitted, except that material may be duplicated by you for your research use 
or educational purposes in electronic or print form. You must obtain permission for 
any other use. Electronic or print copies may not be offered, whether for sale or 
otherwise to anyone who is not an authorized user. 
original article
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 371;1 nejm.org july 3, 201442
Risk of Pediatric Celiac Disease  
According to HLA Haplotype and Country
Edwin Liu, M.D., Hye-Seung Lee, Ph.D., Carin A. Aronsson, M.Sc.,  
William A. Hagopian, M.D., Ph.D., Sibylle Koletzko, M.D., Ph.D.,  
Marian J. Rewers, M.D., M.P.H., George S. Eisenbarth, M.D., Ph.D.,*  
Polly J. Bingley, M.D., Ezio Bonifacio, Ph.D., Ville Simell, M.Sc.,  
Daniel Agardh, M.D., Ph.D., for the TEDDY Study Group†
From the Digestive Health Institute, Chil-
dren’s Hospital Colorado (E.L.), and the 
Barbara Davis Center (E.L., M.J.R., G.S.E.), 
University of Colorado Denver, Aurora; 
the Pediatrics Epidemiology Center, Uni-
versity of South Florida, Tampa (H.-S.L.); 
the Diabetes and Celiac Disease Unit, De-
partment of Clinical Sciences, Lund Uni-
versity, Malmo, Sweden (C.A.A., D.A.); 
Pacific Northwest Diabetes Research In-
stitute, Seattle (W.A.H.); Dr. von Hauner 
Children’s Hospital, Ludwig Maximilian 
University, Munich (S.K.), the Center for Re-
generative Therapies Dresden, Technische 
Universitaet Dresden, Dresden (E.B.), and 
Forschergruppe Diabetes, Helmholz Zen-
trum München, Neuherberg (E.B.) — all in 
Germany; the School of Clinical Sciences, 
University of Bristol, Bristol, United King-
dom (P.J.B.); and the Department of Pedi-
atrics, University of Turku, Turku University 
Hospital, Turku, Finland (V.S.). Address re-
print requests to Dr. Agardh at the Depart-
ment of Pediatrics, Diabetes and Celiac 
Disease Unit, Entrance 72 60:10, Skåne 
University Hospital SUS, SE-20502 Malmo, 
Sweden, or at daniel.agardh@med.lu.se.
*Deceased.
†Members of the Environmental Determi-
nants of Diabetes in the Young (TEDDY) 
Study Group are listed in the Supplemen-
tary Appendix, available at NEJM.org.
This article was updated on July 3, 2014, 
at NEJM.org.
N Engl J Med 2014;371:42-9.
DOI: 10.1056/NEJMoa1313977
Copyright © 2014 Massachusetts Medical Society.
A BS TR AC T
Background
The presence of HLA haplotype DR3–DQ2 or DR4–DQ8 is associated with an in-
creased risk of celiac disease. In addition, nearly all children with celiac disease have 
serum antibodies against tissue transglutaminase (tTG).
Methods
We studied 6403 children with HLA haplotype DR3–DQ2 or DR4–DQ8 prospectively 
from birth in the United States, Finland, Germany, and Sweden. The primary end 
point was the development of celiac disease autoimmunity, which was defined as 
the presence of tTG antibodies on two consecutive tests at least 3 months apart. 
The secondary end point was the development of celiac disease, which was defined 
for the purpose of this study as either a diagnosis on biopsy or persistently high 
levels of tTG antibodies.
Results
The median follow-up was 60 months (interquartile range, 46 to 77). Celiac disease 
autoimmunity developed in 786 children (12%). Of the 350 children who underwent 
biopsy, 291 had confirmed celiac disease; an additional 21 children who did not 
undergo biopsy had persistently high levels of tTG antibodies. The risks of celiac 
disease autoimmunity and celiac disease by the age of 5 years were 11% and 3%, 
respectively, among children with a single DR3–DQ2 haplotype, and 26% and 
11%, respectively, among those with two copies (DR3–DQ2 homozygosity). In 
the adjusted model, the hazard ratios for celiac disease autoimmunity were 2.09 
(95% confidence interval [CI], 1.70 to 2.56) among heterozygotes and 5.70 (95% CI, 
4.66 to 6.97) among homozygotes, as compared with children who had the lowest-
risk genotypes (DR4–DQ8 heterozygotes or homozygotes). Residence in Sweden 
was also independently associated with an increased risk of celiac disease auto-
immunity (hazard ratio, 1.90; 95% CI, 1.61 to 2.25).
Conclusions
Children with the HLA haplotype DR3–DQ2, especially homozygotes, were found 
to be at high risk for celiac disease autoimmunity and celiac disease early in child-
hood. The higher risk in Sweden than in other countries highlights the importance 
of studying environmental factors associated with celiac disease. (Funded by the 
National Institute of Diabetes and Digestive and Kidney Diseases and others.)
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Patients with celiac disease or type 1 diabetes often carry at least one copy of HLA haplotype DR3–DQ2.5cis (DRB1*03-DQA1* 
05:01-DQB1*02:01) or DR4–DQ8 (DRB1*04-DQA1* 
03-DQB1*03:02). The DR3–DQ2.5cis haplotype (char-
acterized by the cis arrangement of DQA1*05:01 
and DQB1*02:01 on the same copy of chromo-
some 6) is present in more than 90% of patients 
with celiac disease. The remainder of patients with 
this disease carry either the aforementioned HLA 
haplotype DR4–DQ8 or the DQ2.5 risk alleles but 
in trans on the genotype DR7–DQ2.2 (DR7-DQA1* 
02:01-DQB1*02:02)/DR5–DQ3.5 (DR5-DQA1*05:01-
DQB1*03:01). The identification of one of these 
haplotypes is not, by itself, sufficient for the diag-
nosis of celiac disease, since both the DR3–DQ2 
and DR4–DQ8 haplotypes are common in the gen-
eral population. The risk of celiac disease differs 
between these two haplotypes, with the presence 
of DR3–DQ2 considered to confer a higher risk 
than the presence of DR4–DQ8. Furthermore, 
the risk associated with each haplotype is prob-
ably influenced by other factors both at birth and 
throughout life.
The Environmental Determinants of Diabetes 
in the Young (TEDDY) is a multinational study 
that follows children at high genetic risk for 
type 1 diabetes, with the development of celiac 
disease as a secondary outcome.2 We assessed 
the incidence of celiac disease autoimmunity 
and celiac disease in children participating in 
this study who were identified at birth as having 
the risk HLA haplotype DR3–DQ2 or DR4–DQ8. 
We also assessed the effects of genotype, sex, 
presence or absence of a family history of celiac 
disease, and country of residence on the risk of 
celiac disease.
Me thods
Study Design
TEDDY is a prospective cohort study involving six 
clinical research centers — three in the United 
States (Colorado, Georgia, and Washington) and 
three in Europe (Finland, Germany, and Sweden). 
The primary objective of TEDDY is to identify ge-
netic, gestational, and environmental risk factors 
for islet autoantibodies, type 1 diabetes, or both 
in children at increased risk for type 1 diabetes 
on the basis of their two HLA haplotypes (HLA 
genotype).3 Because the major HLA genotypes 
that confer a risk of type 1 diabetes also confer a 
risk of celiac disease, we explored the genetic and 
environmental contributions to the development 
of celiac disease auto immunity and celiac disease 
in this cohort.
In TEDDY, all newborns underwent HLA geno-
typing, and those who were found to carry high-
risk genotypes for type 1 diabetes were enrolled 
before 4.5 months of age, with plans for follow-up 
until the age of 15 years. Serum samples were 
obtained from all children every 3 months until 
the age of 48 months and every 6 months there-
after. The HLA genotypes of interest2 are shown 
in Table S1 in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org. 
The presence of the DR4–DQ8/DR8–DQ4 geno-
type allowed the assessment of the effect of one 
copy of DR4–DQ8 in the absence of DR3–DQ2. 
Study Participants
From September 2004 through February 2010, 
we screened 424,788 newborns. Among these in-
fants, 21,589 had one of nine HLA genotypes of 
interest to TEDDY investigators. Of the infants 
carrying a targeted HLA genotype, 8677 were en-
rolled for prospective study; of these infants, 6403 
carried one of the four HLA genotypes reported 
in this study and were tested for serum tissue 
trans glutaminase (tTG) antibodies, a marker for 
celiac disease. The characteristics of the eligible 
children who were enrolled and those who were 
not enrolled in the TEDDY cohort have been de-
scribed previously.4 (Data regarding screening 
and eligibility according to clinical center are 
provided in Table S2 in the Supplementary Ap-
pendix.)
Testing for celiac disease autoimmunity started 
at the 24-month visit and continued yearly. If a 
child tested positive at 24 months, earlier blood 
samples that had been collected from birth on-
ward were also analyzed to determine the age at 
which tTG antibodies first became detectable. 
The persistence of tTG antibodies was confirmed 
by testing of the next available sample from each 
study participant identified as having a positive 
test at any time point.
Measurement of TTG Antibodies
We used radioligand binding assays to measure 
tTG antibody levels in two laboratories.5,6 All se-
rum samples in the United States were screened 
for tTG IgA antibodies at the Barbara Davis Cen-
ter for Childhood Diabetes at the University of 
Colorado in Denver (normal index, <0.05 units). 
In European centers, all serum samples were 
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tested at the University of Bristol in the United 
Kingdom with the use of an assay that detected 
both IgA and IgG antibodies against tTG (nor-
mal index, <1.3 units). Results from these two 
laboratories had previously shown high levels of 
sensitivity and specificity for celiac disease and 
concordance in an international tTG autoantibody 
workshop that included direct comparison with 
commercial enzyme-linked immunosorbent assay 
kits for the detection of IgA antibodies against 
tTG.7 To harmonize the protocol, and on the basis 
of quality-control data,8 we sent all samples with 
tTG antibody levels above 0.01 as assessed in the 
Denver laboratory for quantification of tTG an-
tibodies in the Bristol laboratory, the reference 
laboratory for the study. Results were expressed 
in arbitrary units derived from a standard curve 
consisting of dilutions of serum taken from a 
patient with celiac disease. Samples were consid-
ered to be positive for tTG antibodies if the value 
was 1.3 or more units. The interassay coefficient 
of variation was 22% at both 6 units and 20 units.
Celiac Disease Autoimmunity and Celiac Disease
Celiac disease autoimmunity was defined as the 
presence of tTG antibodies on two consecutive 
tests at least 3 months apart, as measured by the 
Bristol laboratory. Children meeting this primary 
outcome in the TEDDY cohort were referred to a 
gastroenterologist at the clinical discretion of their 
usual physician. The decision about whether to 
perform a biopsy and, if so, when, was outside 
the purview of the study protocol.
Celiac disease, the secondary outcome of the 
study, was defined as an intestinal biopsy sample 
showing a Marsh score of 2 or higher (on a scale 
of 0 to 3, with 0 indicating normal intestinal 
mucosa and 3 indicating atrophied villi and elon-
gated crypts).9 In addition, children who did not 
undergo biopsy but who had a mean tTG anti-
body level of 100 units or higher on two consecu-
tive tests at least 3 months apart were also con-
sidered to have celiac disease for the purposes of 
the study. This threshold was selected on the 
basis of an internal review of all children who 
underwent biopsy, in order to achieve a disease 
specificity of 95% or higher, so that only children 
who did not undergo biopsy but who were very 
likely to have celiac disease were included.
Statistical Analysis
We analyzed two outcomes: the age at which 
celiac disease autoimmunity developed and the 
age at which celiac disease developed. The pri-
mary outcome was defined as the first positive 
result on testing for tTG antibodies, and the right-
censored time (i.e., censoring when the event had 
not yet occurred at the time of measurement) 
was the age at which the last blood sample was 
collected for testing of tTG antibodies. The sec-
ondary outcome was defined as a positive result 
on biopsy or the first high-level result on tTG 
antibody testing (for participants who did not 
undergo biopsy), and the right-censored time 
was the age of the child at the last clinic visit at 
which celiac disease had not been diagnosed. A 
Cox proportional-hazards model was used for 
the analysis, with adjustment for country, sex, 
and presence or absence of a family history of 
celiac disease (i.e., in a first-degree relative). We 
used Fisher’s exact test to compare proportions 
and the log-rank test to compare Kaplan–Meier 
estimates. A P value of less than 0.05 was con-
sidered to indicate statistical significance, with-
out adjustment for multiple testing. All analyses 
were performed with the use of SAS software, 
version 9.2 (SAS Institute).
R esult s
As of July 31, 2013, we had performed tTG anti-
body testing at least once in 6403 children with 
HLA haplotype DR3–DQ2, haplotype DR4–DQ8, 
or both. Of these children, 5778 (90%) had un-
dergone two or more measurements. The mean 
(±SD) follow-up time was 62±20 months; the me-
dian was 60 months (interquartile range, 46 to 77). 
In this cohort, 535 children (8%) had a first-
degree relative with type 1 diabetes, and 144 
(2%) had a first-degree relative with celiac dis-
ease; among the latter children, 22 (<1%) had a 
first-degree relative with both type 1 diabetes 
and celiac disease. The frequency of HLA haplo-
type DR3–DQ2 among children who had a first-
degree relative with celiac disease was higher than 
the frequency among those with no affected fam-
ily members (86% vs. 62%, P<0.001) (Table 1). 
The frequency of the DR4–DQ8/DR8–DQ4 haplo-
type was higher in Finland (32%) than in the 
other countries (P<0.001).
Study Outcomes
Of the 6403 children who were screened, 1026 (16%) 
had at least one positive result of tTG antibody 
testing, and 786 (12%) had persistently positive 
results (the criterion for the primary outcome of 
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celiac disease autoimmunity). Of the 350 children 
who underwent biopsy of the small intestine, 291 
had biopsy confirmation of celiac disease. Two 
children in Europe and 5 in the United States 
received the diagnosis of biopsy-confirmed celiac 
disease after only one positive result on tTG anti-
body testing and therefore did not meet the crite-
rion for persistently positive results. An additional 
21 children with celiac disease autoimmunity 
(6 in Europe and 15 in the United States) had a 
mean tTG antibody level of 100 units or higher 
on consecutive tests but did not undergo confir-
matory biopsy owing to the preference of their 
physicians or parents. These children were also 
considered to have celiac disease for the purposes 
of this study. Thus, 312 children fulfilled the 
study criteria for the diagnosis of celiac disease 
on the basis of biopsy or persistently high anti-
body levels. Celiac disease was diagnosed in one 
quarter of these children before the age of 3 years.
Symptom Questionnaire
The TEDDY questionnaire on celiac disease– 
related symptoms was completed by the families of 
348 of 786 children (44%) with celiac disease au-
toimmunity at the time of the initial tTG antibody 
testing. Of these children, only 94 (27%) were re-
ported to have celiac disease–related symptoms. The 
most frequently reported symptoms were abdomi-
nal discomfort, frequent loose stools, and chronic 
constipation. This symptom pattern did not differ 
significantly among countries (data not shown).
Cumulative Risks According to Genotype
The proportion of children with persistently 
high levels of tTG antibodies was highest 
among those who were homozygous for the 
DR3–DQ2 HLA haplotype: 352 of 1374 children 
(26%), as compared with 298 of 2612 children 
(11%) with the DR3–DQ2/DR4–DQ8 haplotype, 
107 of 1303 (8%) who were homozygous for 
the DR4–DQ8 haplotype, and 29 of 1114 (3%) 
with the DR4–DQ8/DR8–DQ4 haplotype. The 
estimated cumulative risk of celiac disease 
 autoimmunity by the age of 5 years was 26% 
among children who were homozygous for the 
DR3–DQ2 haplotype, 11% among those with 
the DR3–DQ2/DR4–DQ8 haplotype, 9% among 
those who were homozygous for the DR4–DQ8 
haplotype, and 2% among those with the DR4–
DQ8/DR8–DQ4 haplotype (P<0.001 for all com-
parisons) (Fig. 1). Similarly, the cumulative risk 
Table 1. HLA Genotypes of 6403 Children Screened for Celiac Disease.*
Variable HLA DR–DQ Genotype
Total
DR3–DQ2/
DR3–DQ2
DR3–DQ2/
DR4–DQ8
DR4–DQ8/
DR4–DQ8
DR4–DQ8/
DR8–DQ4
number (percent)
All children 6403 (100) 1374 (21) 2612 (41) 1303 (20) 1114 (17)
Family history of type 1 diabetes
Yes 535 (8) 109 (20) 238 (44) 122 (23) 66 (12)
No 5868 (92) 1265 (22) 2374 (40) 1181 (20) 1048 (18)
Family history of celiac disease
Yes 144 (2) 52 (36) 72 (50) 11 (8) 9 (6)
No 6259 (98) 1322 (21) 2540 (41) 1292 (21) 1105 (18)
Sex
Female 3118 (49) 627 (20) 1289 (41) 661 (21) 541 (17)
Male 3285 (51) 747 (23) 1323 (40) 642 (20) 573 (17)
Country
United States 2562 (40) 626 (24) 1064 (42) 533 (21) 339 (13)
Finland 1461 (23) 227 (16) 516 (35) 245 (17) 473 (32)
Germany 344 (5) 81 (24) 163 (47) 68 (20) 32 (9)
Sweden 2036 (32) 440 (22) 869 (43) 457 (22) 270 (13)
* Percentages may not total 100% because of rounding.
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of celiac disease was 11% among children who 
were homozygous for the DR3–DQ2 haplotype, 
3% among those with the DR3–DQ2/DR4–DQ8 
haplotype, 3% among those who were homo-
zygous for the DR4–DQ8 haplotype, and less 
than 1% among those with the DR4–DQ8/DR8–
DQ4 haplotype (P<0.001 for all comparisons).
Nongenetic Risk Factors
Univariate Cox regression analysis showed that the 
risk of celiac disease autoimmunity was signi-
ficantly increased for children who had a first-
degree relative with celiac disease (P<0.001) but 
not for those who had a first-degree relative 
with type 1 diabetes (P = 0.33). Girls were at 
greater risk than boys for celiac disease autoim-
munity, as were children living in Sweden as 
compared with those living in other countries 
(P<0.001 for both comparisons). Swedish resi-
dence remained significantly associated with the 
risk of celiac disease and celiac disease auto-
immunity after adjustment for sex, presence or 
absence of a family history of celiac disease, and 
HLA type. The risk of celiac disease autoimmu-
nity in Sweden was nearly double that in the 
United States (P<0.001). Also, homozygosity for 
the DR3–DQ2 haplotype increased the adjusted 
risk of celiac disease autoimmunity by a factor 
of five, as compared with DR4–DQ8/DR4–DQ8 or 
DR4–DQ8/DR8-DQ4 (the reference group). The 
presence of the DR3–DQ2/DR4–DQ8 genotype 
doubled the risk of celiac disease autoimmunity, 
as compared with the reference group (Table 2).
The risk of celiac disease autoimmunity among 
children who were homozygous for the DR3–DQ2 
haplotype (the highest-risk haplotype) showed 
the same trend as that for celiac disease, with 
the lowest risk among children in the United 
States and the highest risk among those in Swe-
den (P<0.001) (Fig. 2). In the group at highest risk, 
girls who were homozygous for the DR3–DQ2 
haplotype and were born in Sweden, 5 of 12 girls 
(42%) were found to have celiac disease auto-
immunity, as compared with 12% of TEDDY par-
ticipants who did not have all three risk factors 
(P = 0.01).
Diabetes and Celiac Disease
During the course of follow-up, type 1 diabetes 
was diagnosed in 9 of 786 children (1%) with 
celiac disease autoimmunity and in 5 of 312 chil-
dren (2%) with celiac disease. (The risk of diabetes 
is approximately 0.3% in the general population 
of adults and children in the United States.)
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Figure 1. Kaplan–Meier Estimates of Celiac Disease Autoimmunity (CDA), According to HLA Genotype.
Celiac disease autoimmunity was defined as the presence of serum antibodies against tissue transglutaminase (tTG) 
on two consecutive tests at least 3 months apart.
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Discussion
In a large, international, prospective cohort 
study, we found that screening of genetically sus-
ceptible infants can lead to a diagnosis of celiac 
disease at a very early age. These findings may be 
useful in considering future recommendations 
for the initiation of screening in at-risk children. 
We also found that homozygosity for HLA haplo-
type DR3–DQ2 conferred the highest risk of ce-
liac disease autoimmunity and celiac disease in 
all countries that were included in the study and 
was associated with the earliest onset. The risk in 
the group of children with DR3–DQ2 homozy-
gosity was more than 2.5 times that in the group 
with a single DR3–DQ2 haplotype and more than 
5 times that in the lowest-risk groups that we 
studied (DR4–DQ8 homozygotes and DR4–DQ8/
DR8–DQ4 genotype).
These findings confirm the effects of HLA on 
the risk of celiac disease that have been observed 
in earlier prospective studies10-12 and show that 
the DR3–DQ2 haplotype has a gene-dose effect 
on the risk of celiac disease autoimmunity.13-15 
Our findings also confirm the observation that 
DR3–DQ2 homozygosity is associated with an 
earlier age at the onset of celiac disease autoim-
munity.16 In our study, 26% of the children with 
this highest-risk haplotype had celiac disease 
autoimmunity by the age of 5 years. These effects 
are compounded by a family history of celiac 
disease, female sex, and country of residence.
One limitation of our study is that not all 
children underwent intestinal biopsy for confir-
mation of celiac disease, which means that we 
probably underestimated the incidence of celiac 
disease. Most of these children were from clini-
cal sites in the United States. The decision to per-
form a biopsy was clinical and was dependent on 
several factors outside the control of this study. 
In the TEDDY cohort, 83% of children who under-
went biopsy after meeting the primary outcome of 
celiac disease autoimmunity were confirmed to 
have celiac disease. For purposes of this study, 
we also classified an additional 21 children with 
very high tTG antibody levels (≥100 units) as 
having celiac disease. However, these children 
did not meet the current criteria of the Euro-
pean Society for Pediatric Gastroenterology, 
Hepatology, and Nutrition for a clinical diagno-
sis of celiac disease17 because not all the chil-
dren were symptomatic and because endomysial 
Table 2. Hazard Ratios for Celiac Disease Autoimmunity and Celiac Disease.*
Variable Celiac Disease Autoimmunity Celiac Disease
Hazard Ratio
 (95% CI) P Value
Hazard Ratio  
(95% CI) P Value
Country
United States 1.00 1.00
Finland 1.53 (1.26–1.87) <0.001 1.03 (0.73–1.44) 0.88
Germany 1.38 (0.99–1.93) 0.06 0.98 (0.54–1.79) 0.95
Sweden 1.90 (1.61–2.25) <0.001 1.86 (1.43–2.41) <0.001
Sex
Male 1.00 1.00
Female 1.64 (1.42–1.89) <0.001 2.16 (1.71–2.72) <0.001
Family history of celiac disease
No 1.00 1.00
Yes 1.81 (1.31–2.50) <0.001 2.95 (1.95–4.46) <0.001
HLA genotype
DR4–DQ8/DR4–DQ8 or 
DR4–DQ8/DR8–DQ4
1.00 1.00
DR3–DQ2/DR3–DQ2 5.70 (4.66–6.97) <0.001 6.08 (4.43–8.36) <0.001
DR3–DQ2/DR4–DQ8 2.09 (1.70–2.56) <0.001 1.66 (1.18–2.33) 0.004
* The hazard ratio for each variable was adjusted for the other variables in the model.
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antibody testing was not performed. The selec-
tion of this high cutoff point for tTG antibody 
levels means that some cases of celiac disease 
in children with lower tTG antibody levels may 
have been missed. Another limitation is that 
children with the DR3–DQ2/DR4–DQ8 genotype 
were studied but not those with the DR3–DQ2/X 
genotype (i.e., children with only a single celiac-
risk haplotype). Therefore, the added effect of 
DR4–DQ8 on the risk associated with DR3–DQ2 
is unclear, which limits the ability to determine 
the risk conferred independently by a single gene 
dose of DR3–DQ2 in the general population.
In our study, we prospectively applied a stan-
dard protocol across four countries in order to 
eliminate methodologic differences in the search 
for environmental triggers of celiac disease auto-
immunity. This factor has allowed us to make 
the observation that, even after matching for 
haplotype, Swedish children had a substantially 
higher risk of both celiac disease autoimmunity 
and celiac disease than did those from the other 
countries we studied and that celiac disease auto-
immunity developed at an earlier age. The risk 
among Swedish children was nearly double that 
among children in the United States. The reasons 
for a difference in risk between populations with 
a similar genetic predisposition are likely to be 
multifactorial. A sharp and transient increase in 
the incidence of celiac disease in Sweden was 
reported between 1984 and 1996.18 This increase 
was attributed to multiple dietary factors, in-
cluding the interplay between breast-feeding and 
gluten exposure. The age at which gluten is in-
troduced to the diet has been reported to affect 
the risk of celiac disease autoimmunity in ge-
netically predisposed children.19 In the children 
we studied, both the duration of breast-feeding 
and the age at which gluten was introduced var-
ied according to country, which highlights the 
possible complexities of the interactions. The 
overall duration of breast-feeding was longest in 
Finland (median, 39 weeks) and shortest in the 
United States (median, 30 weeks). Swedish children 
were exclusively breast-fed for the longest period 
(median, 4 weeks, as compared with 1 week 
among U.S. children) but were also given gluten-
containing cereals at the earliest age, as com-
pared with children in the other countries.20
Differences in infections in early life may also 
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Figure 2. Kaplan–Meier Estimates of CDA in HLA-DR3–DQ2 Homozygotes, According to Country.
The proportion of children with persistently increased levels of tTG antibodies was highest among those who were 
homozygous for the DR3–DQ2 HLA haplotype. The risk of celiac disease autoimmunity in Sweden was nearly double 
that in the United States.
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be relevant. For example, in one study,21 rota virus 
infection was implicated in the development of 
celiac disease, a finding that requires investiga-
tion in future studies. Our findings indicate the 
need for study of the complex relationships 
among genetic, environmental, and gestational 
factors that may play a role in the development 
of celiac disease in early childhood.
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